Email this article 
Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000
- Authors: Kalinina I.I.1, Shneyder M.M.1, Kirsanova N.P.2, Baydildina D.D.1, Suntsova E.V.1, Goronkova O.V.1, Khachatryan L.A.1, Novichkova G.A.1, Maschan M.A.1, Yutskevich R.I.2, Volochnik E.V.2, Savitskaya T.V.2, Minakovskaya N.V.2, Proleskovskaya I.V.2, Emelyanova I.V.2, Karas O.V.2, Migal N.V.2, Mareyko Y.E.2, Drekov A.G.2, Rumyantseva J.V.1, Fleyshman E.V.3, Nasedkina T.V.4, Aleynikova O.V.2, Maschan A.A.1
-
Affiliations:
- Federal Research Center of Pediatric Hematology, Oncology and Immunology
- Republic Center of Pediatric Oncology and Hematology
- Institute of Cancerogenesis, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
- Issue: Vol 6, No 1 (2011)
- Pages: 11-19
- Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
- Published: 24.02.2011
- URL: https://oncohematology.abvpress.ru/ongm/article/view/100
- DOI: https://doi.org/10.17650/1818-8346-2011-6-1-11-19
- ID: 100
Cite item
Full Text
Abstract
A t(8;21) is the most frequent abnormality in AML in children. Patients with this genetic abnormality are traditionally expected favorable prognosis with a probability of cure up to 80 %. Known additional cytogenetic abnormalities in AML with t(8;21) not affecting prognosis. These include loss of one sex chromosome and del(9q-). Prognosis impact of additional abnormalities involving chromosomes 7 and 11 in patients with t(8;21) is unknown. The purpose of this study was to analyse of additional anomalies, that occur in patients with t(8;21), and their influence on prognosis. During the study period 173 children with AML have received AML-MM-2000 treatment protocol in Russia and Belarus. Of these, in 33 patients (11 girls and 22 boys, median age — 10.5 years) t(8;21) was detected by chromosome banding or molecular-genetic analysis. In group with t(8;21) CNS leukemia in 8 patients was detected, extramedullary lesion — in 8 patients. In 4 patients CNS leukemia combined with presence of extramedullary lesions. These factors did not influence on therapy outcome. Overall survival of AML patients with t(8;21) was 0,67 ± 0,08 compared to 0,44 ± 0,04 in patients with AML without this translocation (p = 0,04). Special subgroup consist of 5 patients with t(8;21) and identified chromosomal abnormalities affecting chromosome 7 and 11, which were a poor prognostic factor: event-free survival in this subgroup of patients (n = 5) was 0,0 ± 0,0, compared to 0,34 ± 0,16 in patients with t(8;21) without additional anomalies (n = 28) (p = 0,027).
Keywords
About the authors
I. I. Kalinina
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Author for correspondence.
Email: burbir@mail.ru
Russian Federation
M. M. Shneyder
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
N. P. Kirsanova
Republic Center of Pediatric Oncology and HematologyRussian Federation
D. D. Baydildina
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
E. V. Suntsova
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
O. V. Goronkova
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
L. A. Khachatryan
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
G. A. Novichkova
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
M. A. Maschan
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
R. I. Yutskevich
Republic Center of Pediatric Oncology and HematologyRussian Federation
E. V. Volochnik
Republic Center of Pediatric Oncology and HematologyRussian Federation
T. V. Savitskaya
Republic Center of Pediatric Oncology and HematologyRussian Federation
N. V. Minakovskaya
Republic Center of Pediatric Oncology and HematologyRussian Federation
I. V. Proleskovskaya
Republic Center of Pediatric Oncology and HematologyRussian Federation
I. V. Emelyanova
Republic Center of Pediatric Oncology and HematologyRussian Federation
O. V. Karas
Republic Center of Pediatric Oncology and HematologyRussian Federation
N. V. Migal
Republic Center of Pediatric Oncology and HematologyRussian Federation
Yu. E. Mareyko
Republic Center of Pediatric Oncology and HematologyRussian Federation
A. G. Drekov
Republic Center of Pediatric Oncology and HematologyRussian Federation
J. V. Rumyantseva
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
E. V. Fleyshman
Institute of Cancerogenesis, N.N. Blokhin Cancer Research Center, Russian Academy of Medical SciencesRussian Federation
T. V. Nasedkina
Engelhardt Institute of Molecular Biology, Russian Academy of SciencesRussian Federation
O. V. Aleynikova
Republic Center of Pediatric Oncology and HematologyRussian Federation
A. A. Maschan
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
References
Supplementary files
